Antipsychotics

Published on 08/04/2015 by admin

Filed under Emergency Medicine

Last modified 08/04/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1822 times

Chapter 161

Antipsychotics

Principles of Disease

Antipsychotic medications are used to treat agitation and psychosis caused by schizophrenia, mania, acute idiopathic psychosis, substance-induced psychosis, and dementia. The antipsychotic medications are divided into three broad categories on the basis of their receptor profiles, clinical effects, and adverse effects (Table 161-1). All antipsychotic medications effectively treat the positive symptoms of psychotic disorders; they reduce hallucinations, control agitation, and aid in restructuring of disordered thinking. In general, the low-potency first-generation antipsychotics (FGAs) are the most sedating. Movement disorders, including extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), are significant problems with both low-potency and high-potency FGAs. In addition to producing less sedation and fewer movement disorders, the atypical or second-generation antipsychotics (SGAs) assist with the negative symptoms of psychotic disorders, such as flat affect, avolition, social withdrawal, and impoverished thought and speech.2 Although neuroleptic malignant syndrome (NMS) occurs with all agents, it occurs least with SGAs.

Anatomy and Physiology

Antipsychotic drugs block dopamine receptors in several areas of the brain, including the cerebral cortex, basal ganglia, limbic system, hypothalamus, and chemoreceptor trigger zone. All antipsychotic agents reduce the positive symptoms of schizophrenia by blocking the dopamine D2 receptor subtype in the mesolimbic region of the brain. However, blockade of D2 receptors in the nigrostriatal brain region produces undesired EPS. In addition, blockade of D2 receptors in the mesocortical brain region impairs cognition and worsens the negative symptoms of schizophrenia. SGAs block both D2 and serotonin 5-HT2A receptors. Because these agents have lower affinity for dopamine receptor antagonism and more selective binding of D2 receptors in the mesolimbic versus nigrostriatal areas of the brain, SGAs should have a lower rate of EPS and TD. The serotonin receptor antagonism is thought to reduce EPS effects and to improve the negative symptoms of schizophrenia.3,4 However, studies have found no significant difference in reported rates of EPS and TD between perphenazine (a FGA) and several SGAs.5,6 Antipsychotic medications also block other receptor types (see Table 161-1).

Some antipsychotic medications have additional clinical uses. The antiemetic effect of prochlorperazine, promethazine, and droperidol is from blockade of dopamine receptors in the chemoreceptor trigger zone of the medulla. Hydroxyzine controls itching by blocking histamine (H1) receptors. Prochlorperazine and droperidol abort migraine headaches by preventing dopamine-mediated meningeal artery vasodilation. Chlorpromazine can treat severe hiccups, and haloperidol is the drug of choice for certain movement disorders, including Tourette’s syndrome and Huntington’s chorea.

Pathophysiology

EPS can be immediate or delayed after initiation of drug therapy. The acute EPS include dystonia, akathisia, and parkinsonism, which are caused by blockade of nigrostriatal D2 receptors and reduced by blockade of muscarinic receptors. The propensity for antipsychotics to produce EPS is inversely proportional to the agents’ muscarinic receptor antagonism.4 The delayed-onset syndromes, including TD and tardive dystonia, develop after prolonged use of antipsychotic medications and are thought to occur from chronic dopamine receptor blockade in the nigrostriatal area leading to D2 receptor upregulation and hypersensitivity to dopamine.79 The pathophysiologic mechanism of NMS, an idiosyncratic reaction to antipsychotic medication, is unknown but thought to be neuroregulatory dysfunction secondary to D2 receptor blockade in the nigrostriatum and hypothalamus, leading to rigidity and hyperthermia, respectively.10 NMS is not associated with ryanodine receptor (RYR) gene mutations, which are associated with malignant hyperthermia.

Antipsychotic medications produce cardiovascular side effects, most commonly orthostatic hypotension with reflexive tachycardia due to alpha-adrenergic blockade. Many agents cause conduction delays, predominantly QT prolongation, resulting in prolonged repolarization and potentially torsades de pointes (TdP).11 The degree of prolongation varies between antipsychotic agents, increasing with dose and with concomitant use of other drugs that prolong the QT interval.12,13 The phenothiazines, particularly thioridazine and mesoridazine, have the greatest risk of cardiac toxicity. QT prolongation has also been reported with the butyrophenones haloperidol and droperidol.12,14 The atypical antipsychotics produce less cardiotoxicity than the traditional agents do, although most can cause repolarization abnormalities in therapeutic doses and overdose.12,15,16 Ultimately, a correlation between QT prolongation and dysrhythmias or TdP has not been established,3 but antipsychotics are associated with an increased risk of sudden death, particularly with heart disease and in elderly patients.17,18 However, psychotic disorders themselves are associated with an increased risk of sudden death.

Clozapine produces agranulocytosis in 1 or 2% of treated patients; however, this has been reduced to 0.4% after strict adherence to labeling requirements.19 Although the mechanism of agranulocytosis is unknown, research supports an immunogenic cause and direct cytotoxic effect on human bone marrow mesenchymal stromal cells.20 Seizure rarely occurs with antipsychotic drugs, but clozapine has the highest seizure incidence. Drug dosing and the patient’s seizure risk profile influence seizure susceptibility.21 FGAs and SGAs have been associated with weight gain, glycemic dysregulation, and dyslipidemia. The cause is not fully understood but partly blamed on the pharmacodynamic profile of these agents.22

Clinical Features

Acute Overdose

In overdose, antipsychotic medications produce signs and symptoms that are exaggerations of the clinical effects. Most patients will have symptoms within a few hours. Central nervous system (CNS) depression is universally present, ranging from mild sedation and confusion to coma and loss of brainstem reflexes. Airway reflexes can be impaired. Respiratory depression can occur after a massive overdose with profound CNS depression. Pupils can be of any size. Mild orthostatic hypotension is a common finding from alpha-adrenergic blockade. Overdose with low-potency FGAs can cause an anticholinergic delirium. EPS have been reported with the FGAs and SGAs.

Atypical antipsychotic overdose is similar to that of traditional antipsychotics. Overdoses are characterized by CNS depression and tachycardia.2330 Miosis may be present, potentially mimicking opioid toxicity.31 Extremity twitching is common. With the exception of clozapine, seizures rarely occur in overdose. Acute EPS have been reported, especially for risperidone overdose.32

Acute Extrapyramidal Syndromes

Acute dystonia is manifested as intermittent, involuntary motor tics or spasms of antagonistic muscle groups that most often involve the facial, neck, back, or limb muscles. This results in trismus, facial grimacing, dysarthria, tongue and lip distortion, torticollis, or oculogyric crisis. Dystonic reactions usually develop within the first several doses of treatment or after a large increase in dosage.33 Laryngeal dystonia is a rare but life-threatening form of dystonia that is manifested as stridor, difficulty in breathing, or choking sensation.5,34 Increased risk of death due to choking has been documented in schizophrenia patients.35

Akathisia is a subjective feeling of restlessness associated with objective motor restlessness, including repetitive foot shuffling, truncal rocking, or pacing. The subjective distress may precipitate aggressive behavior.5,36 Akathisia usually develops within the first few days of treatment, but 40% of patients given 10 mg of intravenous prochlorperazine developed akathisia within 1 hour.37

A parkinsonian syndrome of bradykinesia, masked facies, shuffling gait, muscle rigidity, and resting tremor frequently develops during the first month of treatment; 90% of cases occur within 3 months of treatment. Perioral tremor (rabbit syndrome), in which the lip and nose movements resemble those of a rabbit, can also develop after prolonged therapy.5